Denali Therapeutics Sells Rare Pediatric PRV for $195M to Fund Pipeline Expansion — Denali Therapeutics Inc.

Event summary

Denali Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million.
The PRV was awarded following the FDA approval of AVLAYAH™ for Hunter syndrome in March 2026.
Proceeds will support the advancement of Denali’s clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.
Denali’s TransportVehicle™ platform enables biotherapeutics to cross the blood-brain barrier.

The big picture

Denali Therapeutics’ sale of its Rare Pediatric Disease PRV for $195 million underscores the strategic importance of monetizing regulatory incentives to fund pipeline expansion. The transaction comes on the heels of the FDA approval of AVLAYAH™, validating Denali’s TransportVehicle™ platform as a key differentiator in delivering biotherapeutics across the blood-brain barrier. This move positions Denali to compete more aggressively in the lysosomal storage disorders and neurodegenerative diseases markets, where its proprietary technology offers a significant advantage.

What we're watching

Financial Flexibility: How the $195 million proceeds will impact Denali’s cash runway and ability to accelerate its clinical pipeline.
Pipeline Progress: The pace at which Denali can advance its Enzyme TransportVehicle programs for lysosomal storage disorders and neurodegenerative diseases.
Regulatory Dynamics: Whether the FDA’s accelerated approval program will continue to support Denali’s therapeutic candidates.